Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Whether you’re tracking the next clinical-trial milestone or comparing sales of the Avance Nerve Graft quarter over quarter, Axogen’s SEC documents hold the answers. Investors often ask, “Where can I find Axogen quarterly earnings report 10-Q filing?” or “How do I follow Axogen insider trading Form 4 transactions in real time?”—this page brings everything together.
Stock Titan’s platform delivers AI-powered summaries that turn dense disclosures into clear insights. Our engine flags key metrics—nerve-repair product revenue, R&D spend on regenerative medicine, FDA submissions—and explains them in plain English. Need a quick read of an Axogen annual report 10-K simplified? Interested in understanding Axogen SEC documents with AI before the market opens? Each filing appears here moments after it hits EDGAR, complete with contextual charts and peer comparisons.
- Set alerts for Axogen Form 4 insider transactions real-time to monitor executive stock transactions Form 4.
- Drill into Axogen 8-K material events explained, such as clinical data releases or supply-chain updates.
- Review the Axogen proxy statement executive compensation to see how surgeon-education incentives align with shareholder value.
Because Axogen operates in the highly regulated medical-device arena, each filing carries details on tissue-processing standards, reimbursement risk, and hospital adoption curves—information often buried in footnotes. Our AI surfaces those specifics so you can focus on decisions, not document hunting. Bookmark this hub whenever you need Axogen SEC filings explained simply, from Axogen earnings report filing analysis to the smallest change in risk factors.
Axogen, Inc. insider filed a Form 144 notifying a proposed sale of 7,620 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $136,169.40. The filing lists the number of shares outstanding as 46,012,574 and an approximate sale date of 10/02/2025 on NASDAQ. The securities were acquired as Restricted Stock Units on 09/01/2024 from the issuer and the filing reports "Nothing to Report" for sales in the prior three months. The Form 144 includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Erick DeVinney, listed as Chief Innovation Officer and a director of Axogen, Inc. (AXGN), reported equity activity related to performance stock units. On 09/13/2025 2,500 shares of common stock were issued upon attainment of specified performance criteria, bringing his beneficial ownership to 221,786 shares. To satisfy tax withholding triggered by the vesting, the issuer's plan required a "sell-to-cover" transaction: on 09/16/2025 Mr. DeVinney sold 1,137 shares at $16.29 per share, reducing his beneficial ownership to 220,649 shares. The Form 4 indicates the sale was required by the company election under its equity incentive plans and was not a discretionary trade by the reporting person.
Axogen, Inc. (AXGN) filed an 8-K on August 5, 2025.
The filing furnishes a press release announcing second quarter 2025 financial results (Exhibit 99.1) and a second quarter 2025 financial results presentation posted to the company website and furnished as Exhibit 99.2. The company explicitly states these items are furnished, not filed, and therefore not subject to Section 18 liability or incorporated by reference unless expressly stated in a future filing.
The report is signed by Marc Began, Executive Vice President, General Counsel and Chief Compliance Officer.
Axogen, Inc. (AXGN) – Form 4 insider filing
Director Amy McBride Wendell received an annual equity grant of 14,150 restricted stock units (RSUs) on 06/19/2025. The award is valued at $150,000 and represents the company’s standard director compensation. Each RSU converts to one common share upon vesting, which occurs in a single tranche on 06/19/2026, the one-year anniversary of the grant date. Following the transaction, Wendell’s directly held derivative position totals 14,150 RSUs; no open-market purchases or sales of common stock were reported. The filing does not indicate the adoption of a Rule 10b5-1 trading plan, and no other securities were acquired or disposed of.
Because the award is part of routine board compensation rather than an opportunistic purchase, the filing is unlikely to have a material impact on AXGN’s share price but does underscore continued alignment between the director and shareholder interests through equity-based pay.
Axogen, Inc. (AXGN) filed a Form 4 disclosing that Director Kathy Johnson Weiler received an annual equity grant of 14,150 restricted stock units (RSUs) on 06/19/2025. Each RSU converts into one share of common stock upon vesting, giving Weiler contingent rights to the same number of shares.
The grant is valued at approximately $150,000 based on Axogen’s share price at the grant date and vests in full on 06/19/2026, the one-year anniversary of the award. Following the transaction, the director beneficially owns 14,150 AXGN shares, all held directly. No shares were sold or otherwise disposed of.
The filing reflects routine board compensation, introduces no immediate cash outflow for the company, and does not materially change Axogen’s share count or insider ownership profile.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
